Neutral metoclopramide sensitizes cytotoxicity induced by ionizing radiation in SCID mice xenografted with a human brain astrocytoma

Int J Cancer. 1997 Dec 10;73(6):871-4. doi: 10.1002/(sici)1097-0215(19971210)73:6<871::aid-ijc18>3.0.co;2-7.

Abstract

A formulation of metoclopramide (MCA) conformationally altered by neutralization of pH (nMCA, Neu-Sensamide) has been shown to have the same efficacy of enhancing the cytotoxicity of a single dose of 1 Gy radiation as acidic formulations (e.g., Primperan, Sensamide) in a human lung adenocarcinoma (H2981) xenografted into SCID mice. In the present study, 2 x 1 Gy radiation was combined with 2 x 2 mg nMCA/kg body weight injected 2 hr before radiation treatment for evaluation of radiosensitization in SCID mice xenografted with a human brain astrocytoma (T24). Given in this treatment schedule, nMCA alone at 2 mg/kg showed no cytotoxic effect on tumor growth in vivo. When combined with 2 x 1 Gy of radiation, however, the cytotoxicity was significantly increased as measured by tumor growth delay over the radiation-only-treated group. Furthermore, nMCA was absorbed into brains of mice and rats as efficiently as acidic MCA (aMCA) when analyzed 45 min after i.m. injection by high-performance liquid chromatography.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Astrocytoma / drug therapy
  • Astrocytoma / radiotherapy*
  • Blood-Brain Barrier
  • Body Weight
  • Brain / metabolism
  • Chromatography, High Pressure Liquid
  • Combined Modality Therapy
  • Humans
  • Male
  • Metoclopramide / pharmacokinetics
  • Metoclopramide / therapeutic use*
  • Metoclopramide / toxicity
  • Mice
  • Mice, SCID
  • Neoplasm Transplantation
  • Radiation-Sensitizing Agents / therapeutic use*
  • Tumor Cells, Cultured

Substances

  • Radiation-Sensitizing Agents
  • Metoclopramide